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Abstract 34 
Management of pain in sheep is limited by the challenges of recognising and accurately quantifying 35 
pain in this species. The use of facial expression scoring to assess pain is a well-utilised, practical tool 36 
in both humans and non-human animals. The objective of this study was to develop a standardised 37 
facial expression pain scale for adult sheep, that could be used reliably and accurately to detect pain 38 
associated with naturally occurring painful diseases, such as footrot and mastitis. We also investigated 39 
whether the scale could be reliably and accurately utilised by observers after training, enabling the 40 
development of an on-farm pain assessment tool. The Sheep Pain Facial Expression Scale (SPFES) 41 
was able to correctly identify sheep suffering from disease with a high degree of accuracy (AUC; 42 
Footrot: 0.81, Mastitis: 0.80). Diseased sheep scored higher on the scale than controls on the day of 43 
disease identification (P<0.05) and diseased sheep showed changes in their facial expression after 44 
treatment (P<0.001). The abnormal facial expressions of diseased sheep reduced over time, and at 45 
recovery were in line with control sheep. Control sheep did not change their facial expression over 46 
time. Five scorers who were trained to use the developed scale also assessed the facial expressions of 47 
sheep. The scorers were blind to treatment and session. Scorers reliably (ICC: 0.86) and accurately (α 48 
= 0.86) identified changes in the facial expression of sheep with footrot over time (P<0.05), and 49 
scored control sheep consistently low over time. The SPFES offers a reliable and effective method of 50 
assessing pain in sheep after minimal training.  51 
 52 
Keywords:  53 
Footrot; Sheep; Pain; Facial expression. 54 
 55 
1. Introduction 56 
Pain is an aversive experience with both sensory and affective components, often associated with 57 
actual or potential tissue damage (Broom, 2001; IASP, 1994; Sneddon et al., 2014). Pain can have 58 
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considerable effects on the well-being of an animal and its quality of life. The management of pain in 59 
farm animals however, is often inadequate, resulting in poor welfare (Crook, 2014; Huxley and Whay, 60 
2006). Reasons commonly cited by veterinarians for not administering analgesia to farm animals 61 
include cost to the farmer, withdrawal periods for drug residues and a lack of licensed analgesic 62 
products in some animals such as sheep (although they can be used under “The Cascade System”) 63 
(Lizarraga and Chambers, 2012). One of the major reasons limiting the use of pain relieving drugs in 64 
farm animals is difficulties in recognising and quantifying pain  (Flecknell, 2008; Huxley and Whay, 65 
2006; Ison and Rutherford, 2014; Lizarraga and Chambers, 2012). There is an evident need for an 66 
objective, reliable scoring tool that can be effectively used to recognise and assess pain severity in 67 
sheep. 68 
 69 
Disease is a major source of pain in sheep, impacting negatively upon welfare and adversely effecting 70 
productivity. Footrot in sheep causes severe lameness, a direct sensory response to the tissue damage 71 
caused by the bacteria Dichelobacter nodosus (Kaler et al., 2010a). As lesion severity increases the 72 
degree of lameness observed also increases, indicating the presence of pain (Dolan et al., 2003; Kaler 73 
et al., 2010b). Mechanical threshold responses are also significantly reduced when severe footrot is 74 
present, indicating the presence of chronic pain; the application of a local anaesthetic block raises the 75 
threshold to be in line with that of healthy sheep (Ley et al., 1989). Resolution of the lesions does not 76 
necessarily remove this pain, as hyperalgesia to a mechanical stimulus may still be present for up to 77 
three months in sheep that had previously suffered from severe footrot (Dolan et al., 2003; Ley et al., 78 
1989).  79 
 80 
Mastitis is also regarded as an extremely painful disease in sheep. Mastitis is the inflammation of the 81 
mammary glands usually in response to pathogens such as Staphylococcus aureus and Mannheimia 82 
haemolytica (Jones, 1991). These pathogens can also cause painful lesions within the teat canal 83 
(Mavrogianni et al., 2004). The development of the disease can be rapid, and in severe cases can lead 84 
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to death of the sheep. Sheep with mastitis also show mechanical hyperalgesia (Dolan et al., 2000), 85 
which supports the hypothesis that this is a painful condition.  86 
 87 
Non-steroidal anti-inflammatory drugs (NSAIDs) have antipyretic, anti-inflammatory and analgesics 88 
properties. This supports their use alongside antimicrobials in treating inflammatory conditions such 89 
as footrot and mastitis, to aid recovery and reduce the associated pain. Within veterinary practice, 90 
sheep suffering from mastitis are more likely to receive an NSAID as part of their treatment as it can 91 
rapidly reduce clinical signs of mastitis (Fthenakis, 2000). There is some evidence to also support the 92 
use of NSAIDs when treating sheep with footrot; Welsh and Nolan (1995) administered an NSAID, 93 
flunixin meglumine, to sheep suffering from footrot. They found mechanical hyperalgesia to be 94 
reduced in these sheep compared with sheep that did not receive an NSAID, demonstrating its 95 
analgesic property. Kaler et al. (2010a) assessed the anti-inflammatory property of flunixin 96 
meglumine as an aid to recovery in sheep with footrot. However, they did not find any effect of 97 
NSAIDs on time to recovery when compared with sheep that only received an antibiotic. In sheep, 98 
meloxicam has a longer elimination half-life than flunixin meglumine (10.85 ± 1.21 h, 2.48 ± 0.12 h 99 
respectively) (Cheng et al., 1998; Shukla et al., 2007) and is detectable in blood plasma for up to 72 100 
hours (Shukla et al., 2007) compared to 32 hours for flunixin meglumine (Cheng et al., 1998). These 101 
studies provide evidence for meloxicam to be a better alternative to flunixin meglumine in reducing 102 
inflammation and pain associated with diseases such as footrot and mastitis in sheep. The effect of 103 
meloxicam as an NSAID has not yet been assessed for its ability to reduce pain associated with 104 
disease in sheep.  105 
 106 
Current pain assessment tools commonly use behavioural indicators as these provide sensitive and 107 
non-invasive measures of pain (Mogil and Crager, 2004). Pain related behaviours such as lip curling, 108 
trembling, abnormal postures and vocalisations have been well documented when assessing pain in 109 
lambs undergoing tail docking and castration (Grant, 2004; Guesgen et al., 2014; Molony et al., 110 
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2002). Observing behavioural changes can be time consuming, making it impractical for on-farm 111 
settings. Furthermore, the fluctuating nature of spontaneous pain can mean that smaller, more subtle 112 
changes are likely to be missed (Foss et al., 2006).  113 
 114 
Facial expression scoring systems for pain assessment have been recently developed for use in 115 
rodents, rabbits and horses (Dalla Costa et al., 2014; Langford et al., 2010; Leach et al., 2012). Facial 116 
expression scoring has shown to be successful in identifying and assessing the severity of pain in 117 
animals, with minimal time and training required for observers (Langford et al., 2010; Leach et al., 118 
2012; Sotocinal et al., 2011). Changes in facial expression are likely to be an involuntarily response 119 
by an animal in response to the fluctuating level of pain experienced (Langford et al., 2010) leading to 120 
higher sensitivity in the assessment. The evolutionary stability of facial expression across species 121 
(Williams, 2002) and their use within social contexts (Defensor et al., 2012), suggest that adult sheep 122 
would also be likely to exhibit changes within their facial expression when experiencing pain.  123 
 124 
The objective of the present study therefore, was to develop a standardised facial expression pain 125 
scale that can be used accurately to detect pain associated with naturally occurring painful diseases 126 
such as footrot and mastitis. This objective was achieved by visiting eleven commercial farms across 127 
East Anglia, UK when disease was reported, and evaluating the changes in facial expressions before 128 
and after treatment with antibiotics and during the recovery time. Some of the sheep with footrot were 129 
also treated with an NSAID to evaluate the effect of initial analgesia on the expression of pain in 130 
sheep during recovery from the disease. We also tested whether the SPFES we developed could be 131 
reliably and accurately utilised by observers after training, and thus be a useful and practical on-farm 132 
pain assessment tool.  133 
 134 
2. Methods  135 
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2.1 Ethical statement 136 
Ethical approval was provided by the Department of Veterinary Medicine, University of Cambridge 137 
Ethics and Welfare Committee. All disease incidents were naturally occurring and all animals were 138 
under the supervision of a veterinarian. All sheep suffering from disease were treated appropriately 139 
and revisited throughout the recovery period. No treatment was withheld during the study. Stress to 140 
sheep was minimised when handling or approaching animals. Information was provided to each 141 
farmer before they gave consent for the study to commence on their farm. Informed consent was 142 
obtained from each observer prior to scoring images. All data was anonymised before analysis and no 143 
personal details of the participants were recorded or stored. 144 
 145 
2.2 Footrot 146 
2.2.1 Study population 147 
One hundred and eleven sheep of differing breeds, gender and coat colour were involved in the study. 148 
All the sheep were over one year of age. A total of 73 sheep were diagnosed as having footrot by a 149 
veterinarian, using lameness and lesion scoring. These sheep were matched with 38 control sheep 150 
from the same farm that had no signs of footrot or other disease. Data were collected from October 151 
2012 through to July 2014 across all seasons from eight farms. 152 
 153 
2.2.2 Study design and treatments 154 
All sheep were assessed for lameness using the five point gait scoring method devised by Ley et al. 155 
(1992). All sheep were assessed for footrot lesions using the four point scale developed by Egerton 156 
and Roberts (1971). Sheep were categorised into three treatment groups. Group FA (N=37) were 157 
treated for the presence of footrot with antibiotics, tulathromycin by subcutaneous injection (2.5mg/kg 158 
Draxxin®, Zoetis, Ltd) and topical chlortetracycline (Animedazon® Spray 2.4%, AniMedica). Group 159 
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FAN (N=36) were treated for the presence of footrot as before and also received a non-steroidal anti-160 
inflammatory drug, meloxicam by sub-cutaneous injection (0.5mg/kg, Metacam®, Boehringer 161 
Ingelheim Ltd). Group FC (N=38) showed no signs of lameness and were clinically assessed as being 162 
free from clinical disease by a veterinarian and were used as controls. Controls were matched 163 
carefully on each farm for breed, gender and age.   164 
  165 
Photographic images of sheep faces were taken on the day of disease identification (day 0) after 166 
lameness and lesions were scored. All sheep received an initial treatment on the same day (day 0) 167 
after images had been collected. All sheep were revisited during their recovery period and received 168 
additional treatment as required by the veterinarian, if signs of active disease were still present. 169 
Animals were reassessed for lesions and lameness to establish that they were fully recovered and 170 
facial images were recorded again on day 90.  171 
 172 
2.3 Mastitis 173 
2.3.1 Study population 174 
Twenty nine primiparous and multiparous recently parturient ewes of differing breeds, coat colour 175 
and number of lambs were involved in the study. A total of 17 sheep were identified as having acute 176 
clinical mastitis by a veterinarian. These sheep were matched as closely as possible for days since 177 
parturition and for number of offspring, with a total of 12 control sheep from the same farm identified 178 
as having no signs of clinical mastitis. Data were collected over two lambing seasons (January to July) 179 
in 2013 and 2014 from four farms.  180 
 181 
2.3.2 Study design and treatments 182 
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All sheep were assessed for signs of acute clinical mastitis through udder colour and udder palpation 183 
by a veterinarian. A milk sample from diseased sheep was taken to identify the pathogen and ensure 184 
correct treatment was applied. Sheep were categorised into two treatment groups. Group MAN 185 
(N=17) were treated with an appropriate antibiotic, either tulathromycin by subcutaneous injection 186 
(2.5mg/kg Draxxin®, Zoetis Ltd) or Oxytetracycline by intramuscular injection (10mg/kg Alamycin 187 
LA®, Norbrook Laboratories, Ltd), and all animals received a non-steroidal anti-inflammatory drug, 188 
meloxicam by subcutaneous injection (0.5mg/kg, Metacam®, Boehringer Ingelheim Ltd). Group MC 189 
(N=12) were assessed as being free from clinical disease by the veterinarian and were used as 190 
controls.  191 
  192 
Photographic images of sheep faces were taken on the day of disease identification (day 0) after 193 
udders were assessed. All sheep were treated on the same day (day 0) after images had been recorded. 194 
All sheep were revisited during their recovery period and further images were collected on day 7 and 195 
again on day 42. Animals were reassessed for signs of clinical mastitis to ensure full recovery had 196 
occurred by day 42. If sheep had not responded to the initial treatment, further treatment was provided 197 
by the veterinarian. Sheep were assessed in small groups with their lambs and stress was kept to a 198 
minimum.  199 
 200 
2.4 Image capture  201 
Multiple photographs of sheep were taken from a distance of approximately 1 m using a high 202 
definition camera (Casio®, Exilim HS EX-ZR100, Casio Electronics Co., Ltd., Japan). Photographs 203 
were taken on day 0 after animals had been assessed for presence or absence of disease and had been 204 
left for twenty minutes to settle. Further photographs were taken on day 7 and 42 for mastitis and on 205 
day 90 for footrot before sheep were handled or reassessed for disease presence or absence.  206 
 207 
10 
 
Profile and frontal pictures were taken for each animal on each occasion whilst they remained within 208 
the group. All photographs were cropped to include only the head and to remove body posture, to 209 
prevent observers being influenced by the posture of the animal when scoring the facial expressions as 210 
in Langford et al. (2010) and Leach et al. (2012). The highest quality pictures were used for scoring 211 
where possible. 212 
 213 
2.5 Sheep pain facial scale development 214 
The sheep pain facial expression scale (SPFES) was developed using sheep from the footrot study 215 
group. Footrot was used as our pain model following previous research showing the link between 216 
lameness due to footrot and mechanical hyperalgesia (Ley et al., 1989). We followed methods by 217 
Langford et al. (2010), Sotocinal et al. (2011), Leach et al. (2012), Keating et al. (2012) and Dalla 218 
Costa et al. (2014) to develop our scale. Images of sheep on days 0 and days 90 were compared to 219 
identify changes in facial expression associated with the presence of the disease and lameness. Based 220 
on these comparisons an initial scale was established and trialled  in a pilot study (McLennan et al., 221 
2014). Minor adjustment to the scale with the addition of higher quality photographs and more 222 
detailed descriptors allowed the development of the SPFES (Fig. 1). The scale is used to assess 223 
expression within five facial areas; orbital tightness, cheek tightness, ear position, lip and jaw profile, 224 
and nostril and philtrum position. These areas are scored as having abnormal expression not present, 225 
partially present, or present.  226 
 227 
2.6 Scoring facial expression. 228 
The facial expressions of sheep from both footrot and mastitis were scored separately by an observer 229 
(KM) who was experienced in the use of the scoring system. To reduce possible bias, scoring took 230 
place three months after the scale had been finalised. Photographs that were not in focus or were of 231 
poor quality for angle and light were not scored. To maintain a balanced design, only sheep that had a 232 
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complete set of photographs across all time points were included. Sheep that required more than one 233 
treatment were removed from further analysis. A total of 51 sheep from the footrot group (n, FA=16, 234 
FAN=19, FC=16) and 22 for mastitis (n, MAN =12, MC=10) were scored. The scores from KM were 235 
used to test the sensitivity and specificity of the scale at detecting disease status and thus pain for 236 
mastitis and footrot. The scores were also analysed to determine the effect of time, treatment and a 237 
time*treatment interaction.   238 
 239 
Five treatment and session blind observers who had been given training on how to score the facial 240 
expressions of sheep, scored a sample data set of 60 images from the footrot group consisting of 20 241 
sheep with footrot (n, FOA=9, FOAN=11) and 10 control sheep (FOC). Training consisted of viewing 242 
a pictorial guide with descriptors as well as multiple example images of each of the five facial areas. 243 
This file also included training and testing sections as well as instructions on how to fill out the 244 
scoring file. Training images were not used within the scoring file. The scores from these individuals 245 
after training were used to test the reliability and accuracy of the scale across each treatment group for 246 
the footrot population. The training tool can be found at www.animalwelfarehub.com. 247 
 248 
Two photographs, one profile and one frontal, were assessed for each time point. Images were 249 
presented in a random order generated using a random number generation on Microsoft Excel 7.0. 250 
Both photographs were used to give one score to each of the facial areas using the three-point scale (0 251 
= not present, 1 = partially present, 2 = present). If the two photographs differed in value, or one area 252 
was obscured from view (e.g. nostril and philtrum position can only be seen from the frontal view) the 253 
highest score of the two photographs was given. If an area was not clear on either of the photographs, 254 
it was scored as ‘not able to score’. If two or more areas were scored as ‘not able to score’, the total 255 
score for this image was not included in the analysis. A total pain score (TPS) was determined by 256 
adding the individual scores for each of the five areas for each set of photographs. The maximum 257 
possible score was 10 (i.e. a score of 2 for each of the 5 facial areas). The five observers were also 258 
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asked to make a global assessment of whether they thought the sheep was in pain or not, based on 259 
their own previous experience, as used by Dalla Costa et al. (2014) and Keating et al. (2012).  260 
 261 
2.7 Statistical analysis 262 
Statistical analysis was carried out using Ri386 3.1.1 (R Core Team, 2014) except for receiver 263 
operator curve (ROC) analysis which was carried out using SPSS 22.0 (IBM Corp, 2013). Differences 264 
were considered statistically significant at P < 0.05 and results are reported as mean ± SEM unless 265 
where otherwise stated. Spearman’s rank correlations were calculated to investigate the relationships 266 
between TPS, lameness and the total lesion scores, as this data was not normally distributed. 267 
Spearman’s rank correlations were also calculated between each of the facial areas and the TPS. The 268 
sensitivity (ability of a test to correctly identify animals with the disease) and specificity (ability of a 269 
test to correctly identify animals without the disease) of the scale were calculated. Sensitivity is the 270 
ratio of true positives (TP) to true positives plus false negatives (FN): sensitivity = TP/ TP+FN. 271 
Specificity is the ratio of true negatives (TN) to true negatives plus false positives (FP): specificity = 272 
TN/TN+FP. ROC analysis was carried out by plotting for all cut-off points, the rate of false positives 273 
against the rate of true positives. A value of 1.0 indicates a perfect test, whilst a value of 0.5 indicates 274 
an inadequate test (Lalkhen and McCluskey, 2008). The sensitivity and specificity for each of the TPS 275 
levels was also determined. For footrot groups the outcome was lameness with the predictor as TPS. 276 
For the mastitis group sensitivity and specificity was calculated for the first day only with the 277 
outcome being disease status and the predictor as TPS. A repeated measures linear mixed-effects 278 
model fit by maximum likelihood was used to analyse the TPS across time points (footrot: day 0 and 279 
90; mastitis: day 0, 7 and 42). Day, as the repeated measure was nested within sheep as the random 280 
effect, with treatment group, day, breed and farm as fixed effects. Any time*treatment interactions 281 
were further investigated using analysis of variance with data from separate time periods forming the 282 
dependent variables and treatment as the fixed effect. Post-hoc analysis of treatment group effects was 283 
conducted using Tukey contrast tests. The Kruskal-Wallis test was used to investigate time*treatment 284 
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interactions for the footrot group on day 90 due to data being not normally distributed. Kruskal-Wallis 285 
was also used to investigate time*treatment interactions for the mastitis group for days 7 and 42 due 286 
to data not being normally distributed. In addition, changes in facial expression across days for each 287 
treatment group was calculated and compared to zero using a 1-sample t-test, or a Wilcoxon signed 288 
rank test where data were not normally distributed.  289 
 290 
The global accuracy of the facial pain score was determined by comparing the global pain or no pain 291 
judgement made by treatment and session blinded scorers with the actual disease state of the sheep in 292 
each photograph based upon the lameness and lesion scores (e.g. control or diseased on day 0 and day 293 
90). Reliability of the scale was assessed by comparing the participants’ scores for each area and the 294 
TPS, using the intra-class correlation coefficient (ICC), Cronbach’s alpha.  295 
 296 
3. Results 297 
3.1 Footrot 298 
The TPS scores over the two time periods showed a good accuracy with the area under curve (AUC) 299 
reaching 0.81, compared to lameness. Table 1 shows the sensitivity and specificity of each total facial 300 
expression score. Table 2 gives details on the correlation between facial areas and the TPS. There 301 
were no significant main effects of sheep gender (P=0.47), breed (P=0.12) or farm (P=0.75) on TPS. 302 
Time, treatment and time*treatment had significant effects on TPS (P=0.0001, P=0.0007, P=0.0436 303 
respectively). On day 0 TPS were significantly different between the three treatment groups (F(2,48) = 304 
9.02, P=0.0005), with the TPS being higher in sheep with footrot (groups FA and FAN) compared to 305 
the control group (group FC) (Tukey post-hoc, P<0.01 for both comparisons). No differences were 306 
found between groups that received just antibiotics (FA) and those that received an additional non-307 
steroidal anti-inflammatory drug (FAN) (Tukey post-hoc, P=0.86). At day 90 there were no 308 
significant differences between treatment groups (χ2 = 4.59, df=2, P=0.10) (Fig. 2). Sheep that were 309 
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treated for footrot with antibiotic only, had a decrease in their facial expression score from day 0 to 310 
day 90 (t=-3.29, df=15, P=0.005), as did sheep that received an additional non-steroidal anti-311 
inflammatory drug (V=7.5, P=0.003). Control sheep did not have a change in their facial expression 312 
from day 0 to day 90 (V=18, P=0.18).  313 
 314 
Lameness was correlated positively with total lesion scores (rs = 0.89, P<0.0001). TPS increased as 315 
lameness scores increased (rs = 0.51, P<0.0001) and as total lesion scores increased the TPS also 316 
increased (rs = 0.50, P<0.0001). 317 
 318 
3.2 Mastitis 319 
The facial expression scale showed good accuracy at correctly identifying diseased sheep from control 320 
sheep with AUC of 0.80. Table 1 shows the sensitivity and specificity of each TPS for mastitis sheep 321 
on day 0. Table 2 gives details on the correlation between facial areas and TPS. There were no main 322 
effects of breed (P=0.22) or farm (P=0.31) on TPS. TPS was affected by a time*treatment interaction 323 
(P=0.02). Sheep in group MAN had a higher TPS score (4 ± 0.54) than did sheep in group MC (2 ± 324 
0.47) on day 0 (F(1, 20) = 7.52, P=0.01). There were no significant differences in TPS between 325 
treatment groups for day 7 (χ2=0.01, df=1, P=0.92) and day 42 (χ2 = 0.03, df=1, P=0.87) (Fig. 3). 326 
Sheep in group MAN had a significant decrease in their facial expression score between days 0 and 327 
day 7 (t=-2.15, df=11, P=0.05) and between days 0 and days 42 (t=-9, df=11, P<0.001). The TPS did 328 
not change between day 7 and day 42 for sheep in group MAN (t=-1.61, df=11, P=0.14) and did not 329 
change for sheep in group MC between days 0 and day 7 (t=1.03, df=9, P=0.33), days 0 and day 42 330 
(t=0.133, df=9, P=0.90) and days 7 and 42 (t=-0.58, df=9, P=0.58).  331 
 332 
3.3 Five trained observers 333 
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The average accuracy of the global pain assessment was 67%, with individual accuracy ranging from 334 
60% to 75%. Of the errors, false positives (26.3%) were more common than false negatives (6.3%). 335 
The TPS had a high accuracy in relation to lameness with an AUC of 0.84. Table 1 shows the 336 
sensitivity and specificity of each level of the TPS given by observers. Table 2 gives details on the 337 
correlation between facial areas and TPS. There was a high inter-rater reliability with an overall intra-338 
class correlation (ICC) value of 0.86. Each of the facial areas assessed also showed high (orbital 339 
tightening, 0.90; cheek tightening, 0.82; abnormal ear position, 0.85) to medium ICC values 340 
(abnormal lip and jaw profile, 0.63; and abnormal nose position, 0.65). The five facial areas were 341 
scored easily by all participants as demonstrated by the percentage of “not able to score” ranging from 342 
0% for orbital tightening to 12% for cheek tightening.   343 
 344 
There was a main effect of breed (P=0.02); however, when performing contrasts, there were no 345 
significant differences identified between breeds (P>0.05). There were no significant effects of gender 346 
(P=0.46) or farm (P=0.71) on TPS. Time, treatment and time*treatment interaction had an effect on 347 
TPS (P=0.001, P=0.02, P=0.003, respectively). There were differences between treatment groups on 348 
day 0 (F(2,27) = 11.33, P=0.0003). Sheep in group FOA (4.78 ± 0.49) had a higher TPS than sheep in 349 
group FOC (2.70 ± 0.30) (Tukey post-hoc, P=0.007). Sheep in group FOAN (5.45 ± 0.47) also had a 350 
higher TPS than sheep in group FOC (Tukey post-Hoc, P=0.0002). Sheep in group FOA and group 351 
FOAN did not differ in TPS on day 0. There were no differences in TPS on day 90 between treatment 352 
groups (χ2 = 1, df = 2, P=0.61). Participants did not score sheep in group FOC differently on day 0 353 
compared to day 90 (t=0.33, df=9, P=0.75). Sheep in group FOA had a lower TPS on day 90 354 
compared to day 0 (V=4, P=0.05) as did sheep in group FOAN (t = -5.49, df=10, P=0.0003) (Fig. 4).  355 
 356 
Lameness was correlated positively with total lesion scores (rs = 0.82, P<0.0001). TPS increased as 357 
lameness scores increased (rs = 0.56, P<0.0001) and as total lesion scores increased the TPS also 358 
increased (rs = 0.54, P<0.0001). 359 
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 360 
4. Discussion 361 
 362 
The SPFES developed for this study showed a high degree of accuracy, differentiating between lame 363 
and non-lame sheep correctly, through identifying changes in the facial expressions according to their 364 
level of lameness. These changes in facial expression are similar to those described in other species 365 
with respect to pain (Dalla Costa et al., 2014; Keating et al., 2012; Leach et al., 2012; Sotocinal et al., 366 
2011). Importantly, there were no changes in the facial expression of non-lame sheep. Sheep that had 367 
been suffering from footrot showed high total pain scores that decreased as they recovered. Total pain 368 
scores were positively related to both the total lesion scores and the lameness scores, providing further 369 
evidence for pain in sheep to be both a sensory and emotional experience. The positive correlation 370 
between the level of lameness and severity of footrot lesion observed in our study confirms our choice 371 
of model and is in agreement with other studies (Dolan et al., 2003; Kaler et al., 2011). 372 
 373 
Although we could not differentiate between groups FA and FAN at either time point the provision of 374 
analgesic treatment to sheep with footrot at the time of disease diagnosis appeared to reduce the total 375 
pain score over the 90 day observation period further, compared with sheep that only received an 376 
antibiotic. This result was also noted by the five trained observers whereby the FOAN group had a 377 
larger decrease in their scores between day 0 and day 90 compared with the FOA group. This 378 
decrease in total pain score supports the need to manage pain in sheep with this disease. It is possible 379 
that the use of a non-steroidal anti-inflammatory drug may have reduced the effects of potential 380 
“wind-up” from persistent excitation of the nociceptors involved with the footrot lesions (Stein, 2013; 381 
Viking Höglund and Frendin, 2002); however, further investigation is required. The reduction in pain 382 
could have allowed the sheep to recover more efficiently and resume normal activity before sheep that 383 
had not received this additional treatment. Treatment was given to sheep on day 0 after the 384 
photographs had been taken and so no effect of analgesic would have been occurring at the time of 385 
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photography. Any effect of analgesia would have been detectable up to 72 hours after the 386 
administration of the analgesic as suggested by its elimination half-life (Shukla et al., 2007). In future 387 
studies, it would be beneficial to monitor the changes of facial expression over this time period.  388 
 389 
The high level of specificity for a total pain score above 5 for each of the diseases indicates that a 390 
sheep given this score or above are unlikely to be a false positive. Sheep scoring a total pain score 391 
above 5 are therefore likely to benefit from the administration of pain relief. Although the sensitivity 392 
of the test is low, meaning that some of the diseased animals may go undetected below a TPS of 5, the 393 
overall accuracy of the test is high. It is preferable for a test such as this to have a higher specificity 394 
rate where sheep reaching a high pain score are unlikely to be negative for the painful disease.   395 
 396 
Total facial expression scores at day 90 were not zero. It is possible that hyperalgesia remained a 397 
contributing factor within our study population. Ley et al. (1995) also found sheep previously 398 
diagnosed with footrot were still showing an increased response to mechanical stimulation compared 399 
to control sheep three months after they had seemingly recovered. Control sheep were also not scored 400 
as zero on day 0 or day 90, a finding observed in other studies using facial expression as a pain 401 
scoring system (Dalla Costa et al., 2014; Keating et al., 2012). There are several possible explanations 402 
for this. Control sheep may have had a previous episode of footrot that was not evident at the time of 403 
clinical examination on day 0 and the associated hyperalgesia may have still been present. 404 
Additionally, facial expression may change due to other affective states such as fear and stress, which 405 
can both be related to pain. The development of facial expression scales to help identify other 406 
affective states, both positive and negative, would be beneficial.  407 
 408 
The SPFES also showed a high degree of accuracy in correctly differentiating between sheep with 409 
mastitis and controls. The total pain scores of sheep with mastitis were higher than control sheep on 410 
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day 0 and decreased rapidly in response to treatment by day 7. Facial expressions in sheep with 411 
mastitis did not change significantly from day 7 to day 42 suggesting that the provision of a non-412 
steroidal anti-inflammatory drug as well as antibiotic treatment reduced the associated pain 413 
substantially by day 7. Importantly there were no changes in the facial expression of sheep that acted 414 
as controls across time. These results provide further evidence that the SPFES is accurate at 415 
identifying changes in facial expression that suggest pain in sheep associated with disease.  416 
 417 
The results from the five observers are in line with those given by the more experienced scorer and 418 
demonstrates that the provision of basic training allowed for the effective use of the SPFES to be used 419 
accurately and reliably. In addition, the similarity in results from the main observer and the treatment 420 
and session blinded observers, provides evidence that bias was unlikely to be present in the main 421 
observer. The total pain scores given by the observers correctly identified lame and non-lame sheep, 422 
giving higher scores to lame sheep compared to control sheep on day 0. The observers also scored 423 
sheep at day 90 as low and similar between groups. Observers’ scores also correlated positively with 424 
both the lameness and the lesions scores, supporting the use of the SPFES in identifying pain. The 425 
global pain assessment given by observers was lower (67%) than that of other “Grimace Scales” (97% 426 
for the Mouse Grimace Scale, (Langford et al., 2010), 84% for the Rabbit Grimace Scale (Keating et 427 
al., 2012), but similar to the Horse Grimace Score (73.3%) (Dalla Costa et al., 2014). Scorers were 428 
readily able to identify pain when present, but were cautious in diagnosing absence of pain. In terms 429 
on animal welfare, this is the preferable result. However, the accuracy of the scale improved (up to 430 
84%) when scores given to each area were combined to give a total pain score. This provides support 431 
for the use of the SPFES at identifying pain in sheep in relation to disease, rather than giving a global 432 
assessment. The increase in objectivity through the use of the scale potential helps to remove any fear 433 
of not identifying a sheep in pain correctly. 434 
 435 
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The SPFES scale is reliable between scorers with an overall inter-rater reliability score of 0.86, and 436 
there was high consistency in scores given to the orbital area, the cheek area and ear positioning, 437 
similar findings to others (Keating et al., 2012; Sotocinal et al., 2011). The lip and jaw profile along 438 
with the nostril and philtrum positioning were less reliable between scorers, a result also noticed for 439 
the Horse Grimace Scale (Dalla Costa et al., 2014). The nostril and philtrum position also did not 440 
correlate well with the other areas of the face. This is likely due to the way in which images were 441 
captured. Images for this study were taken as individual photographs rather than still images captured 442 
from video footage. Low image quality and photographs taken at poor angles were avoided wherever 443 
possible; however, there may still be possible negative impacts on effective scoring, a problem noted 444 
within other validation studies of facial expression scales in animals (Dalla Costa et al., 2014; Keating 445 
et al., 2012; Langford et al., 2010).  446 
 447 
Farm and gender did not have any significant effect on the total pain score across treatment group and 448 
time supporting its use as an on farm assessment tool. Breed was only noted to have a significant main 449 
effect on total pain scores in the trained observer group; however, on further investigation there were 450 
no significant differences between breeds found. The anatomical differences between some breeds of 451 
sheep, as well as different colours of the face, may have made it difficult for some observer’s to score 452 
areas effectively. However, the muscle groups involved in facial expression will be the same in each 453 
breed and so the changes in facial areas will be the same movement (see Fig. 1 abnormal ear position 454 
for an example of this). Facial areas were well correlated with the total pain score across diseases. 455 
There are some areas of the face that correlate with each other well; orbital tightening, abnormal ear 456 
position and abnormal lip and jaw profile. Sheep suffering with mastitis had several areas of the face 457 
that were not well correlated with each other. This could be due to the smaller sample size for the 458 
mastitis group, or it could be a factor of the disease state. The systemic nature of mastitis is more 459 
likely to leave sheep dehydrated and therefore some areas of the face may be affected by this, such as 460 
the orbital and cheek area may appear sunken. It is important that a full assessment of any animal is 461 
carried out if disease is suspected and taken into account when scoring the animals. Changes in the 462 
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facial expression occur during other activities such as blinking or chewing which can change the 463 
appearance of the orbital area and cheek area respectively. Every effort was made to eliminate 464 
photographs that may have been taken during these activities; however, using the SPFES to score 465 
animals ‘live’ rather than using still images would resolve many of these problems. Fluctuation in 466 
pain will also result in a fluctuating facial expression. Scoring animals live would identify these 467 
fluctuations through the changes in facial expression and may lead to a better ability at assessing the 468 
intensity of the pain experienced. Future trials for scoring animals live after initial training are 469 
currently being planned to further investigate the use of the SPFES on farm. 470 
 471 
 472 
5. Conclusion 473 
The major challenge for pain research is being able to assess the emotional side of pain (Flecknell et 474 
al., 2011). Facial expression as a pain scoring method offers the potential to start to understand this 475 
side of animal pain (Kunz et al., 2012, 2009) and the results from the current study support this. At 476 
present, the SPFES has been assessed using footrot as the clinical model and successfully applied to 477 
mastitis, a disease causing acute pain in sheep. It is likely that the scale can be used for other 478 
conditions that are suspected of being painful, such as pregnancy toxaemia where the administration 479 
of a non-steroidal anti-inflammatory is known to aid recovery (Zamir et al., 2009). The current scale 480 
provides an accurate and reliable method to recognise and assess pain in sheep. It is also doubles as a 481 
training tool for veterinarians and farmers to learn more about changes in the facial expression of 482 
sheep when they are likely to be suffering from pain. Such a tool is likely to improve an observer’s 483 
ability to quantify pain in animals and allow observers to discriminate between different pain states 484 
independent of disease status, as well as detect the effectiveness of pain relief. Prompt recognition of 485 
pain through the use of the scale will enable farmers and veterinarians to treat and manage their flocks 486 
better, reducing the impact of pain on their sheep, thus improving welfare and production. It is 487 
important to stress that the scale should be used as part of other measures of pain and not as a 488 
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standalone assessment. The provision of the sensitivity and specificity of the scales at each level of 489 
pain will aid scorers in their decision of when to intervene with pain management; something that is 490 
often missing from such scales. This will lead to better management of flocks, leading to better 491 
production values and higher welfare for the sheep.  492 
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Table 1. The sensitivity and 1 - specificity of total facial expression scores for each disease for different positive cut-off points, as scored by the experienced 620 
observer (footrot and mastitis) and by the five trained observers (five observers – footrot). A high sensitivity value indicates a high percentage of sheep 621 
identified as being positive for the disease, if the pain score is greater than or equal to the total pain score value listed. A low 1-specificity value 622 
indicates a high percentage of sheep correctly identified as not having the disease if the pain score is greater than or equal to the total pain score. *Note, 623 
the 1-specificity value of 0.000 indicates all sheep that did not have the disease were not given a total pain score above this level, i.e. they were correctly 624 
identified as not having the disease.  625 
Total pain score: positive if 
greater than or equal to 
 Footrot  Mastitis  Five observers - footrot 
 Sensitivity 1 - Specificity  Sensitivity 1 - Specificity  Sensitivity 1 - Specificity 
1.5  0.927 0.459  1.000 0.600  1.000 0.791 
2.5  0.829 0.311  0.667 0.400  0.941 0.581 
3.5  0.512 0.180  0.667 0.200  0.882 0.395 
4.5  0.293 0.016  0.333 0.000*  0.647 0.163 
5.5  0.171 0.000*  0.167 0.000  0.412 0.047 
6.5  0.049 0.000  - 0.000  0.176 0.000* 
7.5  0.024 0.000  0.083 0.000  0.118 0.000 
9  0.000 0.000  0.000 0.000  0.000 0.000 
 626 
26 
 
Table 2. Correlations between each areas of the face and the total pain score from sheep scored by 627 
KM with footrot represented in the top row, sheep scored by the five trained observers in the middle 628 
row and sheep with mastitis in the bottom row. *P<0.05, **P<0.01, ***P<0.001. 629 
  Orbital 
tightening 
Cheek 
(masseter) 
tightening 
Abnormal 
ear 
position 
Abnormal 
lip and 
jaw profile 
Abnormal 
nostril and 
philtrum 
shape 
Total 
Pain 
Score 
(TPS) 
Orbital 
tightening 
 - 0.32*** 
0.51*** 
0.09 
0.41*** 
0.52*** 
0.37** 
0.26** 
0.42*** 
0.29* 
0.20* 
0.37*** 
0.25 
0.61*** 
0.73*** 
0.66*** 
Cheek 
(masseter) 
tightening 
 0.32*** 
0.51*** 
0.09 
- 0.18 
0.45*** 
0.18 
0.36*** 
0.45*** 
0.26 
0.32*** 
0.47*** 
0.01 
0.60*** 
0.75*** 
0.45*** 
Abnormal ear 
position 
 0.41*** 
0.52*** 
0.37** 
0.18 
0.45*** 
0.18 
- 
 
0.34*** 
0.52*** 
0.37** 
0.20* 
0.50*** 
0.02 
0.64*** 
0.78*** 
0.59*** 
 
Abnormal lip 
and jaw profile 
 0.26** 
0.42*** 
0.29* 
0.36*** 
0.45*** 
0.26 
0.34*** 
0.52*** 
0.37** 
- 0.36*** 
0.63*** 
0.24 
0.47*** 
0.79*** 
0.73*** 
 
Abnormal 
nostril and 
philtrum shape 
 0.20* 
0.37*** 
0.25 
0.32*** 
0.47*** 
0.01 
0.20* 
0.50*** 
0.02 
0.36*** 
0.63*** 
0.24 
- 0.62*** 
0.77*** 
0.55*** 
Total Pain 
Score (TPS) 
 0.61*** 
0.73*** 
0.66*** 
0.60*** 
0.75*** 
0.45*** 
0.64*** 
0.78*** 
0.59*** 
0.47*** 
0.79*** 
0.73*** 
0.62*** 
0.77*** 
0.55*** 
- 
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Orbital tightening 
Not present = 0 Partially present = 1 Present = 2 
There is a closing of the palpebral fissure by the eyelids and a narrowing of the eye 
aperture. If the eye closes more than half way it should be scored as present (2). 
Cheek (masseter muscle) tightening 
Not present = 0 Partially present = 1 Present = 2 
There is a more convex shaping to the cheek in the area of the masseter muscle and 
the zygomatic arch as tension increases. 
Abnormal ear position (front) 
  
 
Not present = 0 Partially present = 1 
Present = 2 
The ears become fully rotated ventrally and caudally and the inner pinna of the ear 
becomes less visible. Note: Baseline (not present) ear carriage varies between 
breeds; however, changes in ear position are the same. 
28 
 
Abnormal ear position (side) 
  
 
 
 
 
 
 
 
Not present = 0 Partially present = 1 Present = 2 
The ears become fully rotated ventrally and caudally and the inner pinna of the ear 
becomes less visible. Note: Baseline (not present) ear carriage varies between 
breeds; however, changes in ear position are the same. 
Abnormal lip and jaw profile 
Not present = 0 Partially present = 1 Present = 2 
The lower lip is drawn back caudally and the jaw profile appears straight to 
concave. The chin and jaw line are straightened. The lip line to the commissure of 
the mouth is straight or even rotated ventrally.  
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Abnormal nostril and philtrum shape 
Not present = 0 Partially present = 1 Present = 2 
As the philtrum is shortened and narrowed increasing a concave appearance of the 
upper lip profile, a ‘V’ shape between nostril apertures is present. The V shape is 
mimicked in the surrounding nose area. 
Fig. 1. The Sheep Pain Facial Expression Scale (SPFES). The Sheep Pain Facial Expression Scale 631 
with images and descriptors of each facial area. Each facial area is scored according to whether it is 632 
not present (score of 0), partially present (score of 1) and present (score of 2). Note: not every facial 633 
area will be present when scoring the expression. Some areas may be expressed at the highest level, 634 
whilst others are not present, in the same sheep.  635 
 636 
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 637 
Fig. 2. Total facial expression pain score (mean ± SEM) of sheep treated for footrot with systemic 638 
antibiotics (FA), with antibiotics plus a non-steroidal anti-inflammatory drug (FAN) and control sheep 639 
(FC), as scored on day 0 and day 90 by an experienced observer. *P<0.05, ** P<0.01 640 
 641 
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 642 
Fig. 3. Total facial expression pain score (mean ± SEM) of sheep treated for mastitis with systemic 643 
antibiotics and a non-steroidal anti-inflammatory drug (MAN) and control sheep (MC), as scored on 644 
day 0, day 7 and day 42 by an experienced observer. * P<0.05. 645 
 646 
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 647 
Fig. 4. Changes in facial expression total pain score (mean ± SEM) from day 0 to day 90 of sheep 648 
treated for footrot with systemic antibiotics (FOA), with antibiotics plus a non-steroidal anti-649 
inflammatory drug (FOAN) and control sheep (FOC), as scored by five trained observers. * P<0.05, 650 
***P<0.001.  651 
